Article
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Blood - 13 Feb 2020
Roboz Gail J, DiNardo Courtney D, Stein Eytan M, de Botton Stéphane, Mims Alice S, Prince Gabrielle T, Altman Jessica K, Arellano Martha L, Donnellan Will, Erba Harry P, Mannis Gabriel N, Pollyea Daniel A, Stein Anthony S, Uy Geoffrey L, Watts Justin M, Fathi Amir T, Kantarjian Hagop M, Tallman Martin S, Choe Sung, Dai David, Fan Bin, Wang Hongfang, Zhang Vickie, Yen Katharine E, Kapsalis Stephanie M, Hickman Denice, Liu Hua, Agresta Samuel V, Wu Bin, Attar Eyal C, Stone Richard M
Abstract excerpt
Ivosidenib (AG-120) is an oral, targeted agent that suppresses production of the oncometabolite 2-hydroxyglutarate via inhibition of the mutant isocitrate dehydrogenase 1 (IDH1; mIDH1) enzyme. From a phase 1 study of 258 patients with IDH1-mutant hematologic malignancies, we report results for 34 patients with newly diagnosed acute myeloid leukemia (AML) ineligible for standard therapy who received 500 mg...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.